MetaCap

CervoMed (CRVO) vs Immutep (IMMP)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Immutep (IMMP) has outperformed CervoMed (CRVO) over the past year, gaining 80.8% versus a loss of 83.6%. Over five years, IMMP leads with a -8.5% price change compared with -95.0% for CRVO. Immutep is the larger company by market cap ($22.9 million vs $22.1 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CRVO-83.56%IMMP+80.81%
+375%+134%-107%
Nov 21, 20251 yearNov 20, 2026
CRVO-95.01%IMMP-18.37%
+115%+5%-105%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CRVO versus IMMP key metrics
MetricCRVOIMMP
Share price$1.46$3.11
Market cap$22.09M$22.92M
1-day change+9.77%-9.06%
YTD return-81.52%+8.74%
1-year return-83.56%+80.81%
5-year return-95.01%-8.53%
EPS (TTM)$-2.65$-7.30
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$4.01M—
Revenue growth (YoY)-58.86%—
Net income (latest FY)$-26.97M—
Operating margin-706.22%—
Net margin-673.06%—
52-week high$10.00$70.60
52-week low$1.27$2.66
Distance from 52-week high-85.40%-95.59%
Analyst consensusstrong_buynone
Avg. price target upside+954.79%+864.63%
Average volume489.10K26.07K
Shares outstanding15.13M7.37M
Employees15—
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • IMMP has outperformed CRVO by 164.4 percentage points over the past year.

About CervoMed

CRVO stock →

CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule drug that crosses the blood–brain barrier and inhibits the enzyme p38a.

Health Care · Biotechnology: Pharmaceutical Preparations · 15 employees

About Immutep

IMMP stock →

Immutep Limited, a clinical-stage biotechnology company, develops lymphocyte activation gene-3 (LAG-3) related immunotherapies for cancer and autoimmune diseases in Australia. The company's lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on the LAG-3 immune control mechanism for the treatment of cancer.

Health Care · Biotechnology: Pharmaceutical Preparations

CRVO vs IMMP FAQ

Which is bigger, CervoMed or Immutep?

Immutep (IMMP) is larger, with a market capitalization of $22.92M compared with $22.09M for CervoMed (CRVO).

Which stock has performed better over the past year, CRVO or IMMP?

IMMP returned +80.81% over the past 12 months, compared with -83.56% for CRVO (price return, excluding dividends). Past performance does not predict future results.

Are CervoMed and Immutep in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons